Clearmind Medicine Inc.
CMNDHealthcare|Biotechnology|CA
$5.58
-0.27 (-4.55%)
DCF Value
$8.03
Tangible Book / Share
$65.03
Cash / Share
$80.54
About
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.
Stock Price
-99.8%(1Y)
1M
-15.4%
3M
-57.2%
6M
-87.3%
YTD
-96.1%
1Y
-99.7%
3Y
-100.0%
5Y
-100.0%
Pipeline Summary
1 total trials1
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 1
Active Trials (1)
A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects
NCT05913752Alcohol Use Disorder
Phase 1Phase 2Recruiting
Enrollment: 84 participants
Key Facts
Market Cap$2.8M
Employees2
CEOAdi Zuloff-Shani
IPO DateNov 15, 2022
Beta-1.21
52-Week Range$5.25 – $2272
Avg Volume65,390
ExchangeNASDAQ
Websiteclearmindmedicine.com
Ownership
Float77.6%
Shares Outstanding0.5M
Recent Insider Trades
HRT FINANCIAL LPSELL
Jun 16, 202622,139 shares @ $3.31
HRT FINANCIAL LPSELL
Jun 15, 20263,183 shares @ $3.32
HRT FINANCIAL LPSELL
Jun 12, 20262,102 shares @ $3.36
HRT FINANCIAL LPBUY
Jun 10, 20262,159,052 shares @ $0.15
HRT FINANCIAL LPSELL
Jun 11, 2026225,191 shares @ $0.12
Peers
Recent News
Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial
Oct 27, 2026 · globenewswire.com
Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets
Oct 12, 2026 · globenewswire.com
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
Oct 8, 2026 · globenewswire.com
Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
Oct 7, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:02 AM